Monopar Therapeutics (MNPR) Free Cash Flow (2017 - 2025)

Monopar Therapeutics (MNPR) has 9 years of Free Cash Flow data on file, last reported at -$3.4 million in Q4 2025.

• For the quarter ending Q4 2025, Free Cash Flow fell 68.64% year-over-year to -$3.4 million; the trailing twelve-month figure through Dec 2025 stood at -$12.2 million (down 90.52% YoY), and the FY2025 full-year result was -$12.2 million, down 90.52% from the prior year.
• Free Cash Flow retreated to -$3.4 million in Q4 2025, from -$2.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$1.1 million in Q3 2024 to a low of -$5.7 million in Q1 2025.
• A 5-year average of -$2.1 million and a median of -$1.9 million in 2021 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow jumped 44.66% in 2024 and slumped 242.11% in 2025, its largest moves.
• Tracing MNPR's Free Cash Flow over 5 years: stood at -$2.0 million in 2021, then jumped by 35.93% to -$1.3 million in 2022, then declined by 18.75% to -$1.5 million in 2023, then slipped by 29.27% to -$2.0 million in 2024, then plunged by 68.64% to -$3.4 million in 2025.
• Business Quant data shows MNPR's Free Cash Flow at -$3.4 million in Q4 2025, -$2.1 million in Q3 2025, and -$1.1 million in Q2 2025.